Ibogaine is often discussed in terms of its potential for transformation. But the possibility of a meaningful experience cannot be separated from the medical risks, ethical responsibilities and systems of care surrounding it.
A recent New York Times investigation, “Americans Encounter Risks at Psychedelic Clinics Abroad,” examined serious incidents reported at psychedelic treatment settings in Latin America. The article raised necessary questions about medical tourism, professional oversight and the limited recourse available when vulnerable people are harmed outside their home countries.
These reports should not be used to discredit every psychedelic treatment provider. Nor should they be dismissed as isolated events from which the wider field has nothing to learn.
They raise a more important question:
What distinguishes a potentially meaningful intervention from an unacceptable risk?
The answer is not found in the substance alone.
The Medicine Is Only One Part of the Treatment
Ibogaine can produce an intense and deeply personal experience. Some people report meaningful changes in their relationship with addiction, trauma and long-established behavioral patterns.
However, the possibility of transformation should never be confused with a guarantee of safety, recovery or a particular outcome.
Ibogaine carries significant medical risks, especially in relation to cardiac function, medication interactions, electrolyte abnormalities and complications associated with substance withdrawal. The psychological experience can also leave a person physically, emotionally and cognitively vulnerable.
The environment surrounding the treatment therefore matters enormously.
Medical screening matters.
Qualified clinical support matters.
Continuous observation matters.
Professional boundaries matter.
Emergency preparedness matters.
Preparation and post-treatment support matter.
A comfortable residence, persuasive testimonials and reassuring language cannot replace these safeguards.
Responsible Ibogaine Care Sometimes Means Saying No
One of the clearest signs of an ethical treatment provider is not how many people it accepts. It is whether the provider is prepared to decline someone when treatment cannot be offered responsibly.
Ibogaine is not appropriate for everyone.
A careful assessment should consider medical history, cardiac health, current medications and supplements, recent substance use, psychiatric stability and the complexity of any required detoxification.
It should also establish whether the person understands what ibogaine can and cannot reasonably provide.
Sometimes the appropriate decision is to delay treatment, request additional medical evaluation or explain that ibogaine is not suitable for that individual.
Turning someone away can be difficult, particularly when that person is suffering and urgently seeking help. But ethical care means refusing to allow commercial considerations, urgency or hope to override clinical judgment.
Vulnerability Creates a Greater Duty of Care
People seeking ibogaine treatment are often not ordinary wellness travelers.
Some arrive after years of addiction, trauma, depression or unsuccessful conventional treatment. They may be physically depleted, emotionally overwhelmed or desperate for something to finally work.
During an altered state of consciousness, this vulnerability can become even greater.
That creates a profound responsibility for everyone involved in their care.
Consent must be informed and ongoing. Professional and personal boundaries must remain clear. The participant’s privacy, dignity and autonomy must be protected before, during and after treatment.
No provider should present themselves as a savior. No profound experience should give a facilitator unchecked authority over another person. No participant should be discouraged from asking questions, expressing discomfort or requesting medical assistance.
Ethics are not an additional feature of psychedelic care. They are part of its foundation.
Experience Must Be Supported by Systems
Years of experience matter, but experience should never be used as a substitute for medical safeguards.
An experienced provider may recognize subtle changes, understand the different phases of an ibogaine experience and know when to remain quietly present or request additional support.
Responsible care, however, cannot depend entirely on one person’s intuition.
It requires a structured system that includes:
- clear eligibility criteria;
- documented medical screening;
- defined clinical responsibilities;
- appropriate cardiac and vital-sign monitoring;
- qualified medical personnel;
- emergency equipment and escalation procedures;
- clinical documentation and communication;
- psychological preparation;
- integration planning and post-treatment support;
- honest communication about potential benefits, limitations and risks.
Safety should remain structured even when the treatment does not unfold as expected.
Emergency Planning Must Exist Before the Emergency
A center should not be evaluated only by what happens when everything goes well.
The more revealing questions are:
- Who recognizes the warning signs?
- Who is qualified and authorized to intervene?
- What monitoring is in place?
- What emergency equipment is immediately available?
- What is the pathway to hospital-level care?
- Who maintains continuity if a transfer becomes necessary?
Emergency preparedness is not an admission that a treatment model is unsafe. It is an acknowledgment that no serious intervention is entirely without risk.
A responsible provider plans for complications before accepting the participant, not after an emergency has already begun.
Accountability Must Accompany Hope
Interest in international psychedelic treatment has developed faster than many of the regulatory systems surrounding it.
This makes transparency and internal accountability particularly important.
Providers should be willing to explain their screening requirements, staffing model, monitoring practices, emergency arrangements and post-treatment structure. They should also communicate their limitations honestly.
Prospective participants deserve more than general assurances that they will be “safe” or “supported.” They should be encouraged to ask specific questions and receive specific answers.
They should also be told clearly that ibogaine is not a cure, outcomes vary, and meaningful recovery usually requires continued work after the experience itself.
How Inner Realms Center Approaches This Responsibility
Caption: Garyth Moxey, Clinical Director and Lead Provider, and Blair Bromley, Founder and Program Director.
At Inner Realms Center in Cuernavaca, Mexico, our approach is guided by a simple principle:
The possibility of transformation never removes our responsibility to protect the person seeking it.
Garyth Moxey, Clinical Director and Lead Provider, brings more than 15 years of direct experience with ibogaine treatment. His role includes participant preparation, presence throughout the treatment process and continued support as the experience is processed afterward.
His experience has reinforced two essential realities: no two participants are identical, and no individual provider should attempt to fulfill every clinical role alone.
Blair Bromley, Founder and Program Director, has structured Inner Realms Center around a deliberately small, clinically supported model. The center accepts a maximum of four participants per treatment cycle, allowing the team to provide close and individualized attention rather than operating through a high-volume model.
For Garyth and Blair, ethical care means communicating honestly, protecting professional boundaries, avoiding promises of specific outcomes and placing participant welfare ahead of the commercial desire to accept every applicant.
Clinical Safeguards at Inner Realms Center
Caption: Clinical monitoring equipment forms part of the treatment safety structure at Inner Realms Center.
Before a participant is cleared for treatment, Inner Realms Center requires a detailed clinical pre-assessment, relevant blood testing and an electrocardiogram.
The participant’s medical history, medications, supplements, substance use and potential contraindications are reviewed before final acceptance.
During the ibogaine flood dose:
- a physician is present on site;
- a dedicated nurse provides care during the critical treatment period;
- cardiac activity is continuously monitored through telemetry;
- vital signs are monitored throughout the process;
- emergency equipment is available;
- paramedic support is incorporated into the safety structure;
- a defined pathway exists for emergency escalation and hospital transfer.
These measures cannot eliminate every possible risk, and Inner Realms Center does not claim that they can.
Their purpose is to reduce avoidable risk and ensure that changes in a participant’s condition can be recognized and addressed promptly.
Care Extends Beyond the Administration of Ibogaine
Safety does not begin with the dose or end when its acute effects subside.
Preparation helps the team understand the participant’s circumstances, clarify expectations and identify factors requiring additional attention before arrival.
Following treatment, stabilization and integration planning help the participant begin processing the experience and consider how any insights may be translated into daily life.
When longer-term or more specialized support is appropriate, referrals to independent professionals can form part of the wider care pathway.
Ibogaine may create an opportunity for change. It cannot make every decision, repair every relationship or build a person’s recovery structure on their behalf.
The Standard the Field Should Demand
Growing interest in ibogaine brings both possibility and responsibility.
The field should welcome scrutiny. It should learn from adverse events rather than become defensive. It should distinguish evidence from marketing and meaningful care from the appearance of care.
Most importantly, it should remember that behind every inquiry is a human being who may be placing their health, future and trust in the hands of people they have only recently met.
That trust should never be taken for granted.
Safety, ethics and accountability must determine how they are received when they arrive.
Learn More About Our Clinical Approach
Inner Realms Center provides clinically supported ibogaine treatment in Cuernavaca, Mexico. Acceptance is subject to individual clinical and medical assessment. Treatment outcomes vary, and no specific result can be guaranteed.
Request Your Clinical Assessment
Disclaimer
Ibogaine treatment involves potential medical and psychological risks. Information provided in this article is for educational purposes only and should not be considered medical advice or a substitute for an individual clinical assessment. Eligibility for treatment is determined on an individual basis by qualified medical professionals. No specific treatment outcome can be guaranteed.
Source
New York Times — “Americans Encounter Risks at Psychedelic Clinics Abroad”
